| Literature DB >> 35559044 |
Chun-Xiao Liu1, Rui-Xing Yin1, Xiao-Li Cao2, Zong-Hu Shi3, Feng Huang1, Bi-Liu Wei1, Guo-Xiong Deng1, Peng-Fei Zheng1, Yao-Zong Guan1.
Abstract
The associations among the EH domain-binding protein 1 (EHBP1), tubulin beta class I (TUBB), and WW domain-containing oxidoreductase (WWOX) single nucleotide polymorphisms (SNPs) and coronary artery disease (CAD) and ischemic stroke (IS) are not yet understood. This study aimed to detect the associations of these SNPs, gene-gene and gene-environment interactions and CAD and IS in the Guangxi Han population. A total of 1853 unrelated subjects were recruited into normal control (n = 638), CAD (n = 622), and IS (n = 593) groups. Related genotypes were determined by high-throughput sequencing. The genotypic and minor allelic frequencies of rs2278075 were different between the CAD and control groups, and those of rs2710642, rs3130685, and rs2278075 were also different between the IS and control groups. The rs2278075T allele, rs3130685-rs2222896-rs2278075, rs3130685-rs2222896-diabetes, rs3130685-rs2222896-drinking, and haplotype rs2710642A-rs10496099C-diabetes interactions were associated with increased risk, while G-T-G-C-G-A and G-T-T-T-G-T-drinking were associated with reduced risk of CAD. The rs2278075T and rs2710642G alleles, rs2710642G-rs10496099C haplotype, rs3130685-rs2278075-rs2222896, and rs2710642-rs2278075-hypertension interactions aggravated the association with IS, whereas the rs3130685T allele, rs2710642A-rs10496099C haplotype and the interactions of H1 (s2710642A-rs10496099C)-H2 (rs2710642G-rs10496099C)-drinking and I1 (A-C-G-C-A-A)-I3 (A-C-G-T-A-A)-I4 (A-C-G-T-G-A)-I5 (G-T-G-C-G-A) diminished the association with IS. Carrying WWOX rs2278075T was strongly associated with CAD or IS, while EHBP1 rs2710642 and TUBB rs3130685 might alter the association of IS by modifying the serum lipid profile. This study demonstrates that the EHBP1, TUBB, and WWOX SNPs, gene-gene and gene-environment interactions are associated with the risk of CAD and IS in the Guangxi Han population.Entities:
Keywords: EH domain-binding protein 1; WW domaincontaining oxidoreductase; coronary artery disease; ischemic stroke; single nucleotide polymorphism; tubulin beta class I
Year: 2022 PMID: 35559044 PMCID: PMC9086287 DOI: 10.3389/fgene.2022.843661
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.772
General and biochemical characteristics of the participants.
| Parameter | Control | CAD | IS |
|
|
|---|---|---|---|---|---|
| Number | 638 | 622 | 593 | ||
| Male/female | 466/172 | 457/165 | 428/165 | 0.863 | 0.734 |
| Age, years | 62.07 ± 12.19 | 62.34 ± 10.50 | 62.85 ± 12.17 | 0.675 | 0.267 |
| Height, cm | 161.76 ± 7.15 | 164.12 ± 6.91 | 163.81 ± 7.19 | 0.000 | 0.000 |
| Weight, kg | 63.41 ± 9.13 | 65.50 ± 10.34 | 64.22 ± 10.28 | 0.000 | 0.145 |
| Body mass index (BMI), kg/m2 | 24.20 ± 2.93 | 24.24 ± 3.10 | 23.87 ± 3.10 | 0.824 | 0.050 |
| Cigarette smoking, | |||||
| 0 cigarette/day | 391 (61.30) | 360 (57.90) | 436 (73.50) | ||
| ≤20 cigarettes/day | 192 (30.10) | 119 (19.10) | 84 (14.20) | ||
| >20 cigarettes/day | 55 (8.60) | 143 (23.0) | 73 (12.30) | 0.000 | 0.000 |
| Alcohol consumption, | |||||
| 0 g/day | 365 (57.20) | 481 (77.30) | 430 (72.52) | ||
| ≤25 g/day | 34 (5.30) | 1 (0.20) | 5 (0.84) | ||
| >25 g/day | 239 (37.50) | 140 (22.5) | 158 (26.64) | 0.000 | 0.000 |
| Systolic blood pressure, mmHg | 129.18 ± 19.45 | 133.34 ± 23.57 | 147.18 ± 22.17 | 0.001 | 0.000 |
| Diastolic blood pressure, mmHg | 81.46 ± 11.70 | 79.34 ± 14.36 | 83.58 ± 13.20 | 0.004 | 0.003 |
| Pulse pressure, mmHg | 47.80 ± 16.36 | 54.00 ± 17.64 | 63.60 ± 17.68 | 0.000 | 0.000 |
| Blood glucose, mmol/L | 6.28 ± 1.36 | 6.23 ± 1.87 | 6.15 ± 1.36 | 0.551 | 0.088 |
| Total cholesterol, mmol/L | 4.58 ± 0.85 | 4.56 ± 1.03 | 4.59 ± 0.97 | 0.665 | 0.982 |
| Triglyceride, mmol/L | 1.45 ± 0.69 | 1.59 ± 0.69 | 1.56 ± 0.73 | 0.000 | 0.003 |
| HDL-C, mmol/L | 1.57 ± 0.50 | 1.17 ± 0.28 | 1.25 ± 0.37 | 0.000 | 0.000 |
| LDL-C, mmol/L | 2.78 ± 0.54 | 2.84 ± 0.73 | 2.83 ± 0.74 | 0.062 | 0.161 |
| Apolipoprotein (Apo)A1, g/L | 1.33 ± 0.25 | 1.04 ± 0.21 | 1.07 ± 0.21 | 0.000 | 0.000 |
| ApoB, g/L | 0.98 ± 0.21 | 0.96 ± 0.22 | 0.98 ± 0.21 | 0.092 | 0.050 |
| ApoA1/ApoB | 1.42 ± 0.40 | 1.14 ± 0.32 | 1.17 ± 0.34 | 0.000 | 0.000 |
| BMI >28 kg/m2, | 63 (9.90) | 69 (11.10) | 68 (11.50) | 0.480 | 0.365 |
| Hypertension, | 113 (17.70) | 116 (18.70) | 194 (32.70) | 0.666 | 0.000 |
| Age >65 years, | 274 (34.50) | 253 (40.70) | 268 (45.20) | 0.414 | 0.427 |
| Type 2 Diabetes, | 139 (21.79) | 133 (21.38) | 113 (19.06) | 0.862 | 0.235 |
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Normally distributed data was described as means ± SD and assessed by Student’s unpaired t-test.
Qualitative data were assessed using the chi-square test.
Nonnormally distributed data were described as medians (interquartile range) and assessed using the Wilcoxon-Mann-Whitney test.
Genotypic and allelic frequencies of the EHBP1, TUBB, and WWOX SNPs in the control and disease groups [n (%)].
| SNP/genotype/allele | Control ( | CAD ( | IS ( |
|
|
|---|---|---|---|---|---|
|
| |||||
| AA | 300 (47) | 301 (48) | 216 (36) | ||
| GA | 281 (44) | 264 (42) | 287 (48) | ||
| GG | 57 (9) | 57 (9) | 90 (15) | 0.848 | 0.000 |
| A | 881 (69) | 866 (70) | 719 (61) | ||
| G | 395 (31) | 378 (30) | 467 (39) | 0.756 | 0.000 |
| | 0.520 | 1.000 | 0.800 | ||
|
| |||||
| CC | 313 (49) | 294 (47) | 283 (48) | ||
| TC | 281 (44) | 261 (42) | 253 (43) | ||
| TT | 44 (7) | 67 (11) | 57 (10) | 0.052 | 0.222 |
| C | 907 (71) | 849 (68) | 819 (69) | ||
| T | 369 (29) | 395 (32) | 367 (31) | 0.122 | 0.273 |
| | 0.083 | 0.460 | 1.000 | ||
|
| |||||
| GG | 427 (67) | 422 (68) | 406 (68) | ||
| GT | 198 (31) | 187 (30) | 175 (30) | ||
| TT | 13 (2) | 13 (2) | 12 (2) | 0.932 | 0.842 |
| G | 1,052 (85) | 1,031 (83) | 987 (83) | ||
| T | 224 (15) | 213 (17) | 199 (17) | 0.774 | 0.610 |
| | 0.076 | 0.160 | 0.190 | ||
|
| |||||
| CC | 184 (29) | 167 (27) | 95 (16) | ||
| CT | 303 (47) | 310 (50) | 299 (50) | ||
| TT | 151 (24) | 145 (23) | 199 (34) | 0.663 | 0.000 |
| T | 605 (47) | 600 (48) | 697 (59) | ||
| C | 671 (53) | 644 (52) | 489 (41) | 0.681 | 0.000 |
| | 0.230 | 1.000 | 0.350 | ||
|
| |||||
| AA | 77 (12) | 102 (16) | 62 (10) | ||
| AG | 312 (49) | 299 (48) | 249 (42) | ||
| GG | 249 (39) | 221 (36) | 282 (48) | 0.073 | 0.011 |
| G | 810 (63) | 741 (60) | 813 (69) | ||
| A | 466 (37) | 503 (40) | 373 (31) | 0.043 | 0.008 |
| | 0.200 | 0.100 | 0.510 | ||
|
| |||||
| AA | 464 (73) | 386 (62) | 353 (60) | ||
| AT | 162 (25) | 208 (33) | 208 (35) | ||
| TT | 12 (2) | 28 (5) | 32 (5) | 0.000 | 0.000 |
| A | 1,090 (85) | 980 (79) | 914 (77) | ||
| T | 186 (15) | 264 (21) | 272 (23) | 0.000 | 0.000 |
| | 0.750 | 1.000 | 0.820 | ||
EHBP1, EH domain-binding protein 1; TUBB, tubulin beta class I; WWOX, WW domain-containing oxidoreductase; SNP, single nucleotide polymorphism; CAD, coronary artery disease; IS, ischemic stroke; HWE, Hardy-Weinberg equilibrium. Qualitative data were assessed using the chi-square test.
Associations between the EHBP1, TUBB, and WWOX SNPs and CAD/IS.
| SNP/Model | Ref. genotype | Alt. genotype | OR 95% CICAD |
| OR 95% CIIS |
|
|---|---|---|---|---|---|---|
| rs2710642 | ||||||
| Codominant | AA | GA | 0.94 (0.74–1.18) | 1.42 (1.12–1.80) | ||
| GG | 1.00 (0.67–1.49) | 0.850 | 2.19 (1.51–3.19) | 0.0001 | ||
| Dominant | AA | GA + GG | 0.95 (0.76–1.18) | 0.630 | 1.55 (1.23–1.95) | 0.0002 |
| Recessive | AA + GA | GG | 1.03 (0.70–1.51) | 0.890 | 1.82 (1.28–2.59) | 0.0007 |
| Overdominant | AA + GG | GG | 1.03 (0.75–1.17) | 0.570 | 1.19 (0.95–1.49) | 0.130 |
| Log–additive | AA | GG | 0.97 (0.82–1.15) | 0.750 | 1.46 (1.23–1.73) | <0.0001 |
| rs10496099 | ||||||
| Codominant | CC | TC | 0.99 (0.78–1.25) | 1.00 (0.79–1.26) | ||
| TT | 1.62 (1.07–2.45) | 0.052 | 1.43 (0.94–2.19) | 0.220 | ||
| Dominant | CC | TC + TT | 1.07 (0.86–1.34) | 0.520 | 1.05 (0.84–1.32) | 0.640 |
| Recessive | CC + TC | TT | 1.63 (1.10–2.43) | 0.015 | 1.44 (0.95–2.16) | 0.083 |
| Overdominant | CC + TT | TC | 0.92 (0.73–1.15) | 0.460 | 0.95 (0.75–1.18) | 0.630 |
| Log–additive | CC | TT | 1.15 (0.97–1.36) | 0.120 | 1.11 (0.93–1.32) | 0.260 |
| rs3132584 | ||||||
| Codominant | GG | GT | 0.96 (0.75–1.22) | 0.93 (0.73–1.19) | ||
| TT | 1.01 (0.46–2.21) | 0.930 | 0.97 (0.44–2.16) | 0.840 | ||
| Dominant | GG | GT + TT | 0.96 (0.76–1.21) | 0.730 | 0.93 (0.73–1.18) | 0.560 |
| Recessive | GG + GT | TT | 1.03 (0.47–2.23) | 0.950 | 0.99 (0.45–2.19) | 0.990 |
| Overdominant | GG + TT | GT | 0.96 (0.75–1.21) | 0.710 | 0.93 (0.73–1.17) | 0.560 |
| Log–additive | GG | TT | 0.97 (0.78–1.20) | 0.770 | 0.94 (0.76–1.17) | 0.600 |
| rs3130685 | ||||||
| Codominant | CC | CT | 1.13 (0.87–1.47) | 0.75 (0.57–0.98) | ||
| TT | 1.06 (0.78–1.44) | 0.660 | 0.39 (0.28–0.54) | <0.0001 | ||
| Dominant | CC | CT + TT | 1.10 (0.86–1.41) | 0.430 | 0.61 (0.48–0.79) | 0.0001 |
| Recessive | CC + CT | TT | 0.98 (0.76–1.27) | 0.880 | 0.47 (0.36–0.62) | <0.0001 |
| Overdominant | CC + TT | CT | 1.03 (0.88–1.20) | 0.400 | 1.12 (0.90–1.41) | 0.300 |
| Log–additive | CC | TT | 1.03 (0.88–1.20) | 0.680 | 0.63 (0.54–0.75) | <0.0001 |
| rs2222896 | ||||||
| Codominant | GG | AG | 1.08 (0.85–1.37) | 0.70 (0.56–0.89) | ||
| AA | 1.49 (1.05–2.11) | 0.073 | 0.71 (0.45–1.03) | 0.010 | ||
| Dominant | GG | AG + AA | 1.16 (0.92–1.46) | 0.200 | 0.71 (0.56–0.89) | 0.0025 |
| Recessive | GG + AG | AA | 1.43 (1.04–1.97) | 0.028 | 0.85 (0.60–1.21) | 0.370 |
| Overdominant | GG + AA | AG | 0.97 (0.78–1.21) | 0.770 | 0.76 (0.60–0.95) | 0.015 |
| Log–additive | GG | AA | 1.19 (1.01–1.40) | 0.041 | 0.79 (0.67–0.94) | 0.075 |
| rs2278075 | ||||||
| Codominant | AA | AT | 1.54 (1.21–1.97) | 1.69 (1.32–2.16) | ||
| TT | 2.80 (1.41–5.59) | 0.0001 | 3.51 (1.78–6.90) | <0.0001 | ||
| Dominant | AA | AT + TT | 1.63 (1.29–2.07) | 0.0001 | 1.81 (1.43–2.30) | <0.0001 |
| Recessive | AA + AT | TT | 2.46 (1.24–4.88) | 0.0072 | 2.98 (1.52–5.83) | 0.0008 |
| Overdominant | AA + TT | AT | 1.48 (1.16–1.88) | 0.0017 | 1.59 (1.24–2.03) | 0.0002 |
| Log–additive | AA | TT | 1.58 (1.29–1.95) | <0.0001 | 1.75 (1.42–2.15) | <0.0001 |
EHBP1, EH domain-binding protein 1; TUBB, tubulin beta class I; WWOX, WW domain-containing oxidoreductase; SNP, single nucleotide polymorphism; CAD, coronary artery disease; IS, ischemic stroke; Ref., reference; Alt., alternate; OR, odds ratio; CI, confidence interval. The OR and 95% CI were calculated by multiple logistic regression analysis and adjusted by stratified eight risk factors, including age, sex, cigarette smoking, alcohol consumption, BMI, type 2 diabetes mellitus, and hypertension. The PCAD or PIS < 0.00021 was considered statistical significance after the Bonferroni correction (6 SNPs × 5 models × 8 factors).
FIGURE 1Associations between the 18 EHBP1, TUBB, and WWOX genotypes and serum lipid parameters in the control group. *p < 0.0004 was considered statistical significance after the Bonferroni correction (6 SNPs × 3 genotypes × 7 lipid phenotypes).
Meaningful associations between the SNPs and serum lipid levels in the control group.
| Lipid | SNP Phenotype | Genotype | Beta |
|
| 95% CI of Beta | ||
|---|---|---|---|---|---|---|---|---|
| Ref. | Alt. | Lower | Upper | |||||
| TC | rs2710642 | AA | GA | 0.144 | 3.571 | <0.0004 | 0.110 | 0.380 |
| AA | GG | 0.186 | 4.594 | <0.0004 | 0.319 | 0.794 | ||
| rs10496099 | CC | TC | 0.179 | 4.502 | <0.0004 | 0.172 | 0.439 | |
| CC | TT | 0.156 | 3.896 | <0.0004 | 0.261 | 0.791 | ||
| rs3132584 | GG | GT | 0.149 | 3.840 | <0.0004 | 0.133 | 0.411 | |
| GG | TT | 0.178 | 4.608 | <0.0004 | 0.634 | 1.576 | ||
| rs3130685 | CC | TT | 0.148 | 3.146 | 0.002 | 0.107 | 0.463 | |
| rs2222896 | AA | AG | −0.258 | −4.105 | <0.0004 | −0.646 | −0.228 | |
| TG | rs2710642 | AA | GA | 0.273 | 7.922 | <0.0004 | 0.286 | 0.475 |
| AA | GG | 0.535 | 15.246 | <0.0004 | 0.360 | 0.554 | ||
| rs10496099 | CC | TC | 0.327 | 9.266 | <0.0004 | 0.172 | 0.439 | |
| CC | TT | 0.434 | 12.240 | <0.0004 | 1.007 | 1.392 | ||
| rs3132584 | GG | GT | 0.438 | 12.510 | <0.0004 | 0.553 | 0.759 | |
| GG | TT | 0.150 | 4.295 | <0.0004 | 0.414 | 1.111 | ||
| rs3130685 | CC | TT | 0.378 | 9.322 | <0.0004 | 0.488 | 0.748 | |
| rs2222896 | AA | AG | −0.647 | −11.274 | <0.0004 | −1.053 | −0.741 | |
| AA | GG | −0.381 | −6.662 | <0.0004 | −0.701 | −0.382 | ||
| HDL-C | rs2710642 | AA | GA | −0.281 | −7.555 | <0.0004 | −0.357 | −0.210 |
| AA | GG | −0.257 | −6.875 | <0.0004 | −0.585 | −0.325 | ||
| rs10496099 | CC | TC | −0.299 | −8.135 | <0.0004 | −0.375 | −0.229 | |
| rs10496099 | CC | TT | −0.222 | −6.017 | <0.0004 | −0.589 | −0.299 | |
| HDL-C | rs3132584 | GG | GT | −0.334 | −9.392 | <0.0004 | −0.437 | −0.286 |
| GG | TT | −0.137 | −3.863 | <0.0004 | −0.159 | −0.247 | ||
| rs2278075 | AA | AT | −0.312 | −8.601 | <0.0004 | −0.441 | −0.277 | |
| LDL-C | rs2710642 | AA | GA | 0.197 | 5.021 | <0.0004 | 0.131 | 0.300 |
| AA | GG | 0.117 | 2.961 | 0.003 | 0.076 | 0.373 | ||
| rs10496099 | CC | TC | 0.215 | 5.565 | <0.0004 | 0.153 | 0.319 | |
| rs3132584 | GG | GT | 0.224 | 5.977 | <0.0004 | 0.177 | 0.351 | |
| ApoA1 | rs2710642 | AA | GA | −0.117 | −2.922 | 0.004 | −0.098 | −0.019 |
| AA | GG | −0.136 | −3.374 | 0.001 | −0.188 | −0.050 | ||
| rs10496099 | CC | TC | −0.125 | −3.153 | 0.002 | −0.101 | −0.023 | |
| CC | TT | −0.137 | −3.425 | 0.001 | −0.211 | −0.057 | ||
| rs3132584 | GG | GT | −0.171 | −4.438 | <0.0004 | −0.131 | −0.051 | |
| GG | TT | −0.129 | −3.385 | 0.001 | −0.371 | −0.099 | ||
| rs3130685 | CC | TT | −0.178 | −3.964 | <0.0004 | −0.154 | −0.052 | |
| ApoA1/ApoB | rs2710642 | AA | GA | −0.153 | −3.786 | <0.0004 | −0.189 | −0.060 |
| AA | GG | −0.154 | −3.792 | <0.0004 | −0.334 | −0.106 | ||
| rs10496099 | CC | TC | −0.163 | −4.071 | <0.0004 | −0.196 | −0.069 | |
| CC | TT | −0.137 | −3.408 | 0.001 | −0.348 | −0.093 | ||
| rs3130685 | CC | TT | −0.193 | −4.259 | <0.0004 | −0.269 | −0.099 | |
Ref., reference; Alt., alternate. Used multivariable linear regression analysis, p < 0.0004 was considered statistical significance after the Bonferroni correction [6 SNPs × 3 genotypes × 7 factors (age, gender, drinking, smoking, hypertension, diabetes and BMI)].
Associations between haplotype frequencies of the two EHBP1 SNPs and CAD or IS [n (frequency)].
| Label | Haplotype | Control [ | CAD [ |
|
| OR [95% CI] CAD | IS [ |
|
| OR [95% CI] IS |
|---|---|---|---|---|---|---|---|---|---|---|
| H1 | A-C | 869 (68.10) | 849 (68.20) | 0.060 | 0.807 | 1.02 (0.86–1.21) | 719 (60.62) | 17.671 | 2.66 × 10−5 | 0.70 (0.59–0.83) |
| A-T | 12 (1.00) | 17 (1.40) | NA | NA | NA | 0 (0.00) | NA | NA | NA | |
| H2 | G-C | 38 (3.00) | 0 (0.00) | NA | NA | NA | 100 (8.44) | 33.385 | 7.76 × 10−9 | 2.94 (2.01–4.30) |
| H3 | G-T | 357 (27.90) | 378 (30.40) | 2.001 | 0.1572 | 1.13 (0.95–1.35) | 367 (30.94) | 2.179 | 0.1399 | 1.14 (0.96–1.36) |
CAD, coronary artery disease; IS, ischemic stroke; A-C, rs2710642A-rs10496099C; A-T, rs2710642A-rs10496099T; G-C, rs2710642G-rs10496099C; G-T, rs2710642G-rs10496099T; n, sample size. NA, not applicable. Lowest frequency thresholds of the four common haplotypes were more than 0.03. Binary logistic regression model was used. p < 0.05 has statistically significant difference.
FIGURE 2Associations between the EHBP1 haplotypes, environmental factors, and their interactions on ischemic stroke. p < 0.025 was considered statistical significance after the Bonferroni correction for two haplotypes. The red and green colors in the picture mean the increased risk and decreased risk factors, respectively.
FIGURE 3Associations between the EHBP1 haplotypes and serum lipid levels in the control group. *p < 0.025 was considered statistical significance after the Bonferroni correction for two haplotypes.
Associations between EHBP1 haplotypes and serum lipid levels in the controls.
| Lipid | Haplotype | Carriers | Beta |
|
| 95% CI of Beta | |
|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||
| TC | A-C | Yes/No | −0.044 | −1.581 | 0.114 | −0.178 | 0.019 |
| G-C | Yes/No | 0.002 | 0.080 | 0.936 | −0.259 | −0.281 | |
| TG | A-C | Yes/No | −0.151 | −5.555 | 0.000 | −0.304 | −0.145 |
| G-C | Yes/No | 0.002 | 0.090 | 0.929 | −0.209 | 0.230 | |
| HDL-C | A-C | Yes/No | 0.104 | 3.957 | 0.000 | 0.056 | 0.167 |
| G-C | Yes/No | −0.008 | −0.297 | 0.766 | −0.175 | 0.129 | |
| LDL-C | A-C | Yes/No | −0.045 | −1.671 | 0.095 | −0.114 | 0.009 |
| G-C | Yes/No | 0.006 | 0.215 | 0.830 | −0.150 | 0.187 | |
| ApoA1 | A-C | Yes/No | 0.077 | 2.844 | 0.005 | 0.013 | 0.069 |
| G-C | Yes/No | −0.008 | −0.297 | 0.766 | −0.089 | 0.066 | |
| ApoB | A-C | Yes/No | −0.001 | −0.040 | 0.968 | −0.025 | 0.024 |
| G-C | Yes/No | 0.031 | 1.118 | 0.264 | −0.028 | 0.104 | |
| ApoA1/ApoB | A-C | Yes/No | 0.051 | 1.841 | 0.066 | −0.003 | 0.091 |
| G-C | Yes/No | −0.028 | −1.004 | 0.316 | −0.194 | 0.063 | |
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; A-C, rs2710642A-rs10496099T; G-C, rs2710642G-rs10496099C; CI, confidence interval. p values were calculated by multivariable linear regression. p < 0.0005 indicates a statistically significant difference after Bonferroni correction for 2 haplotypes, 7 lipid profiles and 7 confounding (age, gender, drinking, smoking, hypertension, fasting blood-glucose, and body mass index).
Frequencies of gene-gene interactions in the control and disease groups [n (frequency)].
| Label | Gene-gene interaction |
|
| OR (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| G1 | G2 | G3 | G4 | G5 | G6 | CAD | Control | ||||
| I 1 | A | C | G | C | A | A | 352 (0.283) | 82 (0.065) | 173.671 | 0.000 | 5.093 (3.897–6.515) |
| I 2 | A | C | G | C | G | A | 104 (0.084) | 316 (0.247) | 160.833 | 0.000 | 0.229 (0.180–0.291) |
| I 3 | A | C | G | T | A | A | 73 (0.059) | 271 (0.213) | 161.899 | 0.000 | 0.191 (0.145–0.252) |
| I 4 | A | C | G | T | G | A | 291 (0.234) | 120 (0.094) | 66.322 | 4.03 × 10−16 | 2.562 (2.033–3.229) |
| I 5 | G | T | G | C | G | A | 66 (0.053) | 118 (0.092) | 22.444 | 2.20 × 10−6 | 0.475 (0.348–0.650) |
| I 6 | G | T | T | T | G | T | 103 (0.083) | 52 (0.041) | 12.758 | 3.57 × 10−6 | 1.860 (1.317–2.626) |
|
|
| ||||||||||
| I 1 | A | C | G | C | A | A | 72 (0.060) | 82 (0.065) | 1.676 | 0.195 | 0.805 (0.580–1.118) |
| I 3 | A | C | G | T | A | A | 77 (0.065) | 271 (0.213) | 142.684 | 7.55 × 10−33 | 0.214 (0.164–0.281) |
| I 4 | A | C | G | T | G | A | 316 (0.266) | 120 (0.094) | 95.527 | 1.56 × 10−22 | 3.046 (2.421–3.834) |
| I 5 | G | T | G | C | G | A | 64 (0.054) | 118 (0.092) | 20.904 | 4.90 × 10−6 | 0.484 (0.353–0.664) |
| I 7 | G | T | G | T | G | A | 103 (0.087) | 17 (0.013) | 60.787 | 6.66 × 10−15 | 6.298 (3.732–10.629) |
G1, EHBP1 rs2710642 G > A; G2, EHBP1 rs10496099 T > C; G3, TUBB rs3132584 G > T; G4, TUBB rs3130685 C > T; G5, WWOX rs2222896 A > G; G6, WWOX rs2278075 A > T; I, interaction. Lowest frequency thresholds of gene-gene interaction were more than 0.03.
Different types of interaction models related to CAD and IS.
| Interactive model | Training bal. acc. | Testing bal. acc. | CV consistency | Sign test | Permutation test |
|---|---|---|---|---|---|
|
| |||||
| SNP-SNP | |||||
| A-B | 0.7184 | 0.7185 | 10/10 | 0.001 | <0.0001 |
| A-B-C | 0.7398 | 0.7332 | 10/10 | 0.001 | <0.0001 |
| A-B-C-D | 0.7657 | 0.7600 | 10/10 | 0.001 | <0.0001 |
| A-B-C-D-E | 0.7792 | 0.7733 | 10/10 | 0.001 | <0.0001 |
| A-B-C-D-E-F | 0.7886 | 0.7787 | 10/10 | 0.001 | <0.0001 |
| SNP-environment | |||||
| A-B-G | 0.7547 | 0.7474 | 10/10 | 0.001 | <0.0001 |
| A-B-H | 0.7245 | 0.7110 | 10/10 | 0.001 | <0.0001 |
| C-D-G | 0.6357 | 0.6270 | 10/10 | 0.004 | 0.971 |
| Haplotype–haplotype | |||||
| H1-H3 | 0.5137 | 0.5028 | 10/10 | 0.187 | 0.398 |
| Haplotype-environment | |||||
| H1-G-I | 0.5754 | 0.5688 | 10/10 | <0.0001 | 0.325 |
| H1-H3-G | 0.5781 | 0.5781 | 10/10 | <0.0001 | <0.0001 |
| Gene-gene | |||||
| I4-I5 | 0.5381 | 0.5234 | 10/10 | 0.404 | 0.027 |
| I2-I4-I5 | 0.5417 | 0.5377 | 10/10 | 0.217 | 0.027 |
| Gene-environment | |||||
| I5-I6-H | 0.6302 | 0.6268 | 10/10 | <0.0001 | <0.0001 |
|
| |||||
| SNP-SNP | |||||
| C-D | 0.8297 | 0.8297 | 10/10 | 0.001 | <0.0001 |
| A-B-C-D | 0.9486 | 0.9411 | 10/10 | 0.001 | <0.0001 |
| A-B-C-D-E | 0.9657 | 0.9601 | 10/10 | 0.001 | <0.0001 |
| A-B-C-D-E-F | 0.9672 | 0.9627 | 10/10 | 0.001 | <0.0001 |
| SNP-environment | |||||
| C-D-J | 0.8297 | 0.8289 | 10/10 | 0.001 | <0.0001 |
| Haplotype–haplotype | |||||
| H1-H2-H3 | 0.5421 | 0.5421 | 10/10 | <0.0001 | <0.0001 |
| Haplotype-environment | |||||
| H1-H2-H | 0.5855 | 0.5855 | 10/10 | <0.0001 | <0.0001 |
| H3-G-K | 0.5493 | 0.5462 | 10/10 | <0.0001 | <0.0001 |
| Gene-gene | |||||
| I3-I4 | 0.5447 | 0.5447 | 10/10 | <0.0001 | <0.0001 |
| I3-I4-I5 | 0.5770 | 0.5770 | 10/10 | <0.0001 | <0.0001 |
| I1-I3-I4-I5 | 0.5827 | 0.5827 | 10/10 | <0.0001 | <0.0001 |
A = rs3130685, B = rs2222896, C = rs2278075, D = rs2710642, E = rs3132584, F = rs10496099, G = diabetes mellitus, H = drinking, I = female, J = hypertension, K = age >65 years; Bal. Acc., balanced accuracy; CV, cross-validation. H1, haplotype A-C; H3, haplotype G-T; I1, A-C-G-C-A-A; I3, A-C-G-T-A-A; I4, A-C-G-T-G-A; I5, G-T-G-C-G-A. Sign test p < 0.05 indicates a statistically significant different, and permutation test p < 0.001 has a statistically significant difference after Bonferroni correction 6 SNPs and 7 confounding (age, gender, drinking, smoking, hypertension, fasting blood-glucose, and body mass index).
Risk of CAD or IS with different types of interactions.
| Variable 1 | Variable 2 | OR (95% CI) |
|
|---|---|---|---|
|
| |||
| SNP-SNP interaction | |||
| rs3130685 | rs2222896 | ||
| CC | AA | 1 | – |
| CT + TT | AG + GG | 1.293 (1.023–1.635) | 0.032 |
| CT + TT | AA | 1 | – |
| CC | AG + GG | 1.088 (0.863–1.415) | 0.533 |
| Haplotype-environment interaction | |||
| H1 | DM | ||
| Non-carriers | No | 1 | – |
| Carriers | Yes | 1.528 (1.271–1.970) | 0.000 |
| Non-carriers | Yes | 1 | – |
| Carriers | No | 0.825 (0.700–0.972) | 0.022 |
| Gene-gene interaction | |||
| I2 | I5 | ||
| Non-carriers | Carriers | 1 | – |
| Carriers | Non-carriers | 0.875 (0.671–1.141) | 0.325 |
| Carriers | Non-carriers | 1 | – |
| Non-carriers | Carriers | 0.611 (0.446–0.837) | 0.002 |
| Gene-environment interaction | |||
| I6 | Drinking | ||
| Non-carriers | No | 1 | – |
| Carriers | Yes | 1.294 (0.288–5.810) | 0.736 |
| Carriers | No | 1 | – |
| Non-carriers | Yes | 0.285 (0.234–0.348) | 0.000 |
|
| |||
| SNP-SNP interaction | |||
| rs3130685 | rs2278075 | ||
| CC | AA | 1 | – |
| CT + TT | AT + TT | 1.212 (0.939–1.564) | 0.140 |
| CT + TT | AA | 1 | – |
| CC | AT + TT | 0.852 (0.503–1.443) | 0.551 |
| rs3130685 | rs2222896 | ||
| CC | AA | 1 | – |
| CT + TT | AG + GG | 2.025 (1.580–2.596) | 0.000 |
| CT + TT | AA | 1 | – |
| CC | AG + GG | 0.613 (0.459–0.818) | 0.001 |
| rs2710642 | rs2278075 | ||
| AA | AA | 1 | – |
| GA + GG | AT + TT | 4.723 (3.661–6.095) | 0.000 |
| GA + GG | AA | 1 | – |
| AA | AT + TT | 8.740 (5.935–12.871) | 0.000 |
| Haplotype-environment interaction | |||
| H1 | Drinking | ||
| Non-carriers | No | 1 | – |
| Carriers | Yes | 0.463 (0.364–0.589) | 0.000 |
| Carriers | No | 1 | |
| Non-carriers | Yes | 0.606 (0.447–0.822) | 0.001 |
| H2 | Drinking | ||
| Non-carriers | No | 1 | – |
| Carriers | Yes | 1.314 (0.634–2.721) | 0.463 |
| Carriers | No | 1 | – |
| Non-carriers | Yes | 0.435 (0.353–0.535) | 0.000 |
H1, haplotype rs2710642A-rs10496099C; H2, haplotype rs2710642G-rs10496099C; I2, rs2710642A-rs10496099C-rs3132584G-rs3130685C-rs2222896G-rs2278075A; I5, rs2710642G-rs10496099T-rs3132584C-rs3130685C-rs2222896G-rs2278075A; I6, rs2710642G-rs10496099T-rs3132584T-rs313068T5-rs2222896G-rs2278075T; OR, odds ratio; CI, confidence interval. Different types of interactions were analyzed by logistic regression. p < 0.001 indicates a statistically significant difference after Bonferroni correction and adjusting for six SNPs and seven confound factors.
FIGURE 4Optimal interactions affecting diseases shown in a dendrogram. Elements that interact strongly with each other appear close together in the leaves of the tree, while elements that interact weakly appear far from each other. The yellow, orange and red colors indicate synergy effect between two factors, and blue and green colors indicate redundancy effect between two factors. The darker the color, the stronger the effect.